Trial Profile

Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Lithium (Primary) ; Temozolomide (Primary)
Indications Glioma
Focus Therapeutic Use

Most Recent Events

05 Nov 2015 Time Frame for primary endpoint changed from 6 months to 50 months as per NCT.
12 Jan 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
26 Feb 2014 Planned End Date changed from 1 Apr 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com